Marker Therapeutics, Inc. (MRKR) Institutional Ownership

Ownership Summary

A total of 35 institutions have reported a stake in Marker Therapeutics, Inc. (NASDAQ:MRKR) as of December 2025, according to recent 13F filings with the SEC.

• Marker Therapeutics saw its institutional ownership percentage rose to 33.5% in December 2025 from 29.5% in September 2025.
• Quarterly data indicates a 17.85% shift in institutional share volume, and the annual owner count reflects an increase of 2.94%.
• During the quarter, 18 institutions bought more Marker Therapeutics shares, 3 sold shares, and 14 of the 35 total investors held their position steady.
• The total number of shares held by institutions in Marker Therapeutics increased to 3.90Mn as of December 2025, a net change of up by 589.96K shares quarter on quarter, and down 563.21K shares year over year.
• NEA Management Company, LLC's holding of 1.63Mn shares as of December 31, 2025 makes it the primary institutional investor in Marker Therapeutics, owning 13.99% of the stock.
• Among the most significant buyers of Marker Therapeutics during December 2025 were UBS Group AG (168.23K), TWO SIGMA INVESTMENTS, LP (61.60K), CITADEL ADVISORS LLC (58.85K), XTX Topco Ltd (58.04K), VANGUARD GROUP INC (46.29K).
• Leading sellers of Marker Therapeutics stock in December 2025 included CITIGROUP INC (9.27K), Invst, LLC (2.00K), MORGAN STANLEY (446).
• The top 10 institutional holders of Marker Therapeutics for the quarter ending December 2025 included NEA Management Company, LLC (1.63Mn), Blue Owl Capital Holdings LP (554.25K), VANGUARD GROUP INC (346.07K), Aisling Capital Management LP (325.37K), UBS Group AG (174.03K), GEODE CAPITAL MANAGEMENT, LLC (130.34K), RENAISSANCE TECHNOLOGIES LLC (123.65K), TWO SIGMA INVESTMENTS, LP (98.14K), OSAIC HOLDINGS, INC. (94.42K), LPL Financial LLC (83.25K).